Skip to main content

Table 1 Patient characteristics (n = 84)

From: Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial

Characteristic Whole population (n = 84) Number (%)
Median age, years (range) 50.5(28–70)
Amenorrhea
 Premenopausal 36 (42.9)
 Postmenopausal 48 (57.1)
Advanced or metastatic
 De novo metastatic 12 (14.3)
 Metastatic 72 (85.7)
No. of metastatic sites
 1 6 (7.1)
 2 31 (36.9)
 ≥ 3 47 (56.0)
Metastatic sites
 Visceral 69 (82.1)
 Lung 39 (46.4)
 Liver 48 (57.1)
 Non-visceral 15 (17.9)
 Bone 46 (54.8)
Subgroup
 Luminal 61 (72.6)
 Triple-negative 12 (14.3)
 HER2 positive 10(11.9)
 Unknown 1(1.2)
Lines of chemotherapy
 First line 59(70.2)
 Second line or more line 25(29.7)
Prior chemotherapy
Adjuvant/neoadjuvant (n = 65)
 Anthracycline-containing 63 (96.9)
 Taxane-containing 49 (75.4)
 Both 47 (72.3)
Chemotherapy for MBC (n = 25)
 Anthracycline-containing 6 (24)
 Taxane-containing 10 (40)
 Both 3(12)